Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
a Cancer Research Campaign Section of Medicine and Gastrointestinal Unit, Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey
Correspondence to: Dr D Cunningham, Department of Medicine, The Royal Marsden Hospital, Sutton, Surrey SM2 5PT Series editor: G M Mead (G M Mead is consultant in medical oncology at the Cancer Research Campaign's Wessex Medical Oncology Unit).
Patients with oesophageal, gastric, and pancreatic carcinomas present a common and difficult problem for the clinician. Surgery is the best option for curative treatment but overall survival figures remain low. Recent improvements in our understanding of the biology of these tumours and improvements in their clinical staging, along with the development of combined modality approaches to local-regional disease, have led to renewed optimism that survival figures may be improved. This is particularly so for oesophageal and gastric carcinomas. In addition, there have been advances in the palliative management of all three tumours. This article examines some of these developments and looks at future prospects.
Epidemiology and pathology
Oesophageal cancer
Oesophageal cancer accounts for around 2% of cancer deaths in the United Kingdom annually. The diagnosis is associated with a median survival of 10 months, and fewer than 5%
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?